Evidence map›Paper›PMID 36090893›Full record

ArticleJournal of oncology2022

Engineered Exosomes Loaded with miR-563 Inhibit Lung Cancer Growth.

Weiwei Gao, Nan Yang, Chunyang Yin, Yi Zeng, Xiaoping Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. [Research Progress of Engineered Exosomes in the Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiwei GaoDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Nanjing Medical University, Shanghai 200120, China.
Nan YangDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Chunyang YinDepartment of Tuberculosis, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China.
Yi ZengDepartment of Tuberculosis, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China.
Xiaoping ZhuDepartment of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Nanjing Medical University, Shanghai 200120, China.ORCID https://orcid.org/0000-0002-6295-2985

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The malignancy of lung cancer (LC) is serious in the world. Exosomes are well-known natural nanovesicles, which are reported to have the potential to carry functional miRNAs as natural carriers and deliver chemotherapeutic drugs. However, the safety and functions of the engineered exosomes for delivering miRNA for the treatment of LC remain to be evaluated. In this study, we found that miR-563 is related to lung cancer from GeneCard database. RT-qPCR and in situ hybridization (ISH) were used to assess miR-563 expression in clinical samples. We prepared and verified the engineered exosomes loaded with miR-563 both

Identifiers

PMID36090893
PMCPMC9462977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.